MOXILONE – 400 Tablet

Adept Antibiotic with Extended Spectrum of Activity & Higher Pathogen Eradication Rate

COMPOSITION: Moxifloxacin hydrochloride 400 mg 



COMPOSITION: Moxifloxacin hydrochloride 400 mg 

On average, adults have two or three colds a year and children have six to ten colds a year, of which only about 2% are complicated by acute bacterial sinusitis.


Drug class: Fluoroquinolones

  • A 4th generation fluoroquinolone with a broad spectrum of activity against microorganisms isolated in Community Acquired Pneumonia (CAP), including multi-resistant pneumococci and pathogens such as M. catarrhalis and H. influenzae with resistance to penicillins, macrolides, and tetracyclines.
  • Provided excellent clinical and bacteriological cure rates in CAP due to drug-resistant Streptococcus pneumococci.
  • A better microbiological effect and lower risk of treatment failures of moxifloxacin can be attributed to its excellent tissue penetration, high bioavailability, and bactericidal mechanism.
  • Possesses activity against atypical pathogens and meta-analysis data suggests that it alone has a higher pathogen eradication rate than β-lactam-based combination therapy.
  • Moxifloxacin was as clinically equivalent and bacteriologically superior to the antibiotic regimens routinely used in patients with Acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease.


 Moxifloxacin hydrochloride 400 mg